Literature DB >> 1565898

The role of renal-sparing surgery for renal cell carcinoma.

A C Novick1.   

Abstract

Nephron-sparing surgery provides effective therapy for patients with localized RCC in whom preservation of renal function is a relevant clinical consideration. The technical success rate with this approach is excellent, and long-term patient survival free of cancer is comparable with that obtained after radical nephrectomy, particularly for stage I RCC. The major disadvantage of conservative surgery is the approximately 10% risk of postoperative local tumor recurrence. The risk of local recurrence after radical nephrectomy has not been determined but is presumably less. The indications for nephron-sparing surgery in patients with unilateral RCC and a completely normal opposite kidney are not established, and radical nephrectomy should still be considered the treatment of choice in this setting.

Entities:  

Mesh:

Year:  1992        PMID: 1565898

Source DB:  PubMed          Journal:  Semin Urol        ISSN: 0730-9147


  4 in total

Review 1.  Risk of chronic kidney disease after cancer nephrectomy.

Authors:  Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

2.  Margin and complication rates in clampless partial nephrectomy: a comparison of open, laparoscopic and robotic surgeries.

Authors:  Luigi Mearini; Elisabetta Nunzi; Alberto Vianello; Manuel Di Biase; Massimo Porena
Journal:  J Robot Surg       Date:  2016-04-15

3.  Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer.

Authors:  Hung-Jui Tan; Edward C Norton; Zaojun Ye; Khaled S Hafez; John L Gore; David C Miller
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

Review 4.  Current Status of Minimally Invasive Surgery for Renal Cell Carcinoma.

Authors:  Zachary L Smith
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.